Arden R Barry

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2532415/arden-r-barry-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65	1, 000 citations	12	3 O
papers		h-index	g-index
77	1,332 ext. citations	2.3	4.62
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
65	Omega-3 fatty acids for cardiovascular disease prevention: A practice tool for pharmacists <i>Canadian Pharmacists Journal</i> , 2022 , 155, 169-174	1.3	
64	Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2021 , 23, 578-589	12.3	5
63	Review of the top 5 cardiology studies of 2019-20. Canadian Pharmacists Journal, 2021, 154, 388-393	1.3	
62	Therapeutic Controversies in the Medical Management of Valvular Heart Disease. <i>Annals of Pharmacotherapy</i> , 2021 , 55, 1379-1385	2.9	1
61	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 1129-1150	3.8	62
60	Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease. <i>Pharmacotherapy</i> , 2021 ,	5.8	3
59	Longitudinal Oral Anticoagulant Adherence Trajectories in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2395-2404	15.1	3
58	Medication management for heart failure with reduced ejection fraction: Clinical pearls for optimizing evidenced-informed therapy <i>Canadian Family Physician</i> , 2021 , 67, 915-922	0.9	
57	Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists. <i>Canadian Pharmacists Journal</i> , 2020 , 153, 153-160	1.3	O
56	Colchicine for Secondary Cardiovascular Prevention: A Systematic Review. <i>Pharmacotherapy</i> , 2020 , 40, 575-583	5.8	3
55	Pharmacist- or Nurse Practitioner-Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. <i>Canadian Journal of Hospital Pharmacy</i> , 2020 , 73, 186-192	0.5	1
54	Review of the top 5 cardiology studies of 2017-18. Canadian Pharmacists Journal, 2020, 153, 32-36	1.3	2
53	Treatment of chronic noncancer pain in patients on opioid therapy in primary care: A retrospective cohort study. <i>Canadian Pharmacists Journal</i> , 2020 , 153, 52-58	1.3	3
52	The case for independent pharmacist prescribing. Canadian Pharmacists Journal, 2020, 153, 319-320	1.3	
51	Developments in Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 2215	27.4	
50	Physical assessment educational programs for pharmacists and pharmacy students: A systematic review. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020 , 4, 211	1.4	1
49	COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Canadian Pharmacists Journal</i> , 2020 , 153, 193-197	1.3	O

48	Assessment of Condition and Medication Knowledge Gaps Among Atrial Fibrillation Patients: A Systematic Review and Meta-analysis. <i>Annals of Pharmacotherapy</i> , 2019 , 53, 773-785	2.9	8
47	Evaluation of Physical Assessment Education for Practising Pharmacists: A Cross-Sectional Survey. <i>Canadian Journal of Hospital Pharmacy</i> , 2019 , 72, 27-33	0.5	3
46	Health Authority PharmacistsTPerceptions of Independent Pharmacist Prescribing. <i>Canadian Journal of Hospital Pharmacy</i> , 2019 , 72, 185-193	0.5	О
45	Newer Oral Antihyperglycemics: From to. Canadian Journal of Hospital Pharmacy, 2019 , 72, 385-387	0.5	
44	Anticoagulant Utilization and Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular Atrial Fibrillation. <i>Canadian Journal of Hospital Pharmacy</i> , 2019 , 72, 428-434	0.5	2
43	Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization. <i>CJC Open</i> , 2019 , 1, 297-304	2	
42	Assessment of atrial fibrillation patientsTeducation needs from patient and clinician perspectives: A qualitative descriptive study. <i>Thrombosis Research</i> , 2019 , 173, 109-116	8.2	12
41	Long-Term Beta-Blocker Therapy after Myocardial Infarction in the Reperfusion Era: A Systematic Review. <i>Pharmacotherapy</i> , 2018 , 38, 546-554	5.8	14
40	Prevention and management of statin adverse effects: A practical approach for pharmacists. <i>Canadian Pharmacists Journal</i> , 2018 , 151, 179-188	1.3	9
39	PatientsTperceptions and use of natural health products. Canadian Pharmacists Journal, 2018, 151, 254	1-21632	19
38	Primary care and the RCMP: Unexpected partnership in opioid harm reduction. <i>Canadian Family Physician</i> , 2018 , 64, 489-490	0.9	1
37	Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis. <i>Current Diabetes Reviews</i> , 2018 , 14, 273-279	2.7	10
36	Coenzyme Q10 for statin-associated myalgia. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 15	2.2	1
35	Coenzyme Q10 supplementation in the management of statin-associated myalgia. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, 786-793	2.2	7
34	A Systematic Review of Add-on Pharmacologic Therapy in the Treatment of Resistant Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2017 , 17, 311-318	4	11
33	Review of the top 5 cardiology studies of 2015-16. Canadian Pharmacists Journal, 2017, 150, 380-386	1.3	2
32	Influenza Vaccination for Secondary Prevention of Cardiovascular Events: A Systematic Review. <i>Canadian Journal of Hospital Pharmacy</i> , 2017 , 70, 27-34	0.5	11
31	Patient-Centred Care through Storytelling. Canadian Journal of Hospital Pharmacy, 2017, 70, 322-323	0.5	1

30	Development of a Pharmacist REferral Program in a primary cARE clinic (PREPARE): A prospective cross-sectional study. <i>Canadian Pharmacists Journal</i> , 2017 , 150, 206-215	1.3	4
29	Cardiovascular safety outcomes of new antidiabetic therapies. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, 970-976	2.2	4
28	Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis. <i>Journal of Cardiology</i> , 2017 , 69, 353-358	3	6
27	The bus analogyTA new analogy to help pharmacy students conceptualize the well-stirred model. <i>Currents in Pharmacy Teaching and Learning</i> , 2017 , 9, 639-643	1.5	
26	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1263-1282	3.8	543
25	Applying the guidelines for pharmacists integrating into primary care teams. <i>Canadian Pharmacists Journal</i> , 2016 , 149, 219-25	1.3	5
24	Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. <i>Canadian Family Physician</i> , 2016 , 62, 32-7	0.9	26
23	DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics. <i>Canadian Journal of Hospital Pharmacy</i> , 2016 , 69, 253-4	0.5	2
22	Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. <i>Canadian Journal of Hospital Pharmacy</i> , 2016 , 69, 280-5	0.5	1
21	Omega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular disease. <i>Canadian Pharmacists Journal</i> , 2016 , 149, 166-73	1.3	24
20	What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, e229-37	2.2	1
19	Primary Prevention of Cardiovascular Disease in Older Adults. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1074-81	3.8	14
18	Pharmacotherapy of heart failure with preserved ejection fraction. <i>Pharmacotherapy</i> , 2015 , 35, 351-60	5.8	17
17	Review of the top 5 cardiology studies of 2013-14. Canadian Pharmacists Journal, 2015, 148, 349-54	1.3	3
16	Professional use of social media by pharmacists. <i>Canadian Journal of Hospital Pharmacy</i> , 2015 , 68, 22-7	0.5	15
15	Clozapine-Associated Myocarditis: Case Report and Literature Review. <i>Canadian Journal of Hospital Pharmacy</i> , 2015 , 68, 427-9	0.5	9
14	Single vs Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Implantation: A Systematic Review. <i>Clinical Cardiology</i> , 2015 , 38, 629-34	3.3	4
13	Adverse drug reactions: The importance of maintaining pharmacovigilance. <i>Canadian Pharmacists Journal</i> , 2014 , 147, 233-8	1.3	2

LIST OF PUBLICATIONS

12	One good note. Canadian Journal of Hospital Pharmacy, 2014 , 67, 250	0.5	
11	Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery. <i>Pharmacotherapy</i> , 2014 , 34, 464-72	5.8	7
10	Case report and review of clenbuterol cardiac toxicity. <i>Journal of Cardiology Cases</i> , 2013 , 8, 131-133	0.6	18
9	Review of the top 5 cardiology studies of 2011-12. Canadian Pharmacists Journal, 2013, 146, 213-7	1.3	4
8	Patient satisfaction with services provided by multidisciplinary anticoagulation clinics. <i>Pharmacotherapy</i> , 2013 , 33, 1246-51	5.8	6
7	Triple antithrombotic therapy in patients with atrial fibrillation who have undergone percutaneous coronary intervention with stent implantation. <i>American Journal of Health-System Pharmacy</i> , 2012 , 69, 1485-93	2.2	5
6	An evaluation of teaching physical examination to pharmacists. <i>Canadian Pharmacists Journal</i> , 2012 , 145, 174-179.e1	1.3	17
5	Reasons for non-use of proven pharmacotherapeutic interventions: systematic review and framework development. <i>Journal of Evaluation in Clinical Practice</i> , 2012 , 18, 49-55	2.5	9
4	A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 708-14	3.2	54
3	Prescribing by Pharmacist's and Collaborative Care: Are We Ready to Accept the Baton and Get in the Race?. <i>Canadian Journal of Hospital Pharmacy</i> , 2010 , 63, 59	0.5	
2	Is it ethical for health care organizations to charge institutions for experiential rotations?. <i>Canadian Journal of Hospital Pharmacy</i> , 2009 , 62, 331-4	0.5	
1	Reasons for Non-use of Proven Interventions for Hospital Inpatients: PharmacistsTPerspectives. <i>Canadian Journal of Hospital Pharmacy</i> , 2009 , 62, 381-5	0.5	3